Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1979 1
1980 4
1981 8
1982 9
1983 6
1984 9
1985 18
1986 13
1987 22
1988 23
1989 38
1990 42
1991 18
1992 32
1993 43
1994 46
1995 56
1996 62
1997 65
1998 68
1999 90
2000 100
2001 122
2002 128
2003 195
2004 207
2005 258
2006 295
2007 332
2008 432
2009 472
2010 498
2011 619
2012 678
2013 762
2014 898
2015 1035
2016 1064
2017 1179
2018 1277
2019 1487
2020 1714
2021 2017
2022 2466
2023 2351
2024 2729
2025 3160
2026 251

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24,486 results

Results by year

Filters applied: . Clear all
Page 1
iMeta Conference 2025: Creating high-impact international journals.
Zhu Z, Zhang L, Yao X, Zeng M, Wang Y, Luo H, Zhou Y, Zhang T, Xun J, Bai D, Yang H, Xu S, Zhou Y, Gao Y, Xu J, Han W, Shen Z, Zhang B, Ma T, Wan XL, Ma C, Hui F, Bai H, Bai L, Bai Q, Bao Q, Cao G, Cao P, Cao Q, Chen H, Chen J, Chen J, Chen L, Chen T, Chen Y, Cui H, Dai S, Dai XJ, Dai X, Dang Y, Deng L, Deng Y, Ding X, Dong B, Dong L, Dou S, Du H, Fang Z, Feng X, Fu M, Gao Y, Gong W, Guo X, Han W, Hao Z, He ZG, Hu H, Hu H, Hu X, Huang L, Huang X, Huang X, Hui H, Jia D, Jiang A, Jiang D, Jiang K, Jiang D, Jin Y, Lai K, Li C, Li F, Li F, Li J, Li J, Li J, Li K, Li L, Li M, Li P, Li P, Li R, Li S, Li S, Li W, Li W, Li X, Li X, Li X, Liang Q, Liao X, Liu B, Liu C, Liu C, Liu D, Liu F, Liu J, Liu J, Liu S, Liu T, Liu W, Liu Y, Liu Y, Liu Y, Liu Y, Liu Y, Liu Z, Liu Z, Lu X, Luo X, Ma G, Meng J, Meng Y, Miao R, Miao L, Ni Y, Niu D, Niu T, Pan H, Qin G, Qiu T, Qiu Y, Qu H, Qu L, Ren N, Sun Q, Shang R, She P, Shen X, Shi B, Shu Y, Song J, Song W, Su Q, Sun Q, Sun Y, Sun Z, Tang B, Tang D, Tang H, Tao Y, Teng T, Tu Y, Wang C, Wang H, Wang Y, Wang C, Wang D, Wang G, Wang J, Wang K, Wang M, Wang S, Wang S, Wang X, Wang XC, Wang Y, Wang J, Wang Z, Wang W, Wei Y, Xu W, Wu F, Wu J, Wu S,… See abstract for full author list ➔ Zhu Z, et al. Among authors: jin y. Imeta. 2025 Oct 15;4(6):e70086. doi: 10.1002/imt2.70086. eCollection 2025 Dec. Imeta. 2025. PMID: 41472845 Free PMC article.
Deep contrastive learning enables genome-wide virtual screening.
Jia Y, Gao B, Tan J, Zheng J, Hong X, Zhu W, Tan H, Xiao Y, Tan L, Cai H, Huang Y, Deng Z, Wu X, Jin Y, Yuan Y, Tian J, He W, Ma W, Zhang Y, Liu L, Yan C, Zhang W, Lan Y. Jia Y, et al. Among authors: jin y. Science. 2026 Jan 8;391(6781):eads9530. doi: 10.1126/science.ads9530. Epub 2026 Jan 8. Science. 2026. PMID: 41505557
Deriving consensus sepsis clusters via goal-directed subgroup identification in multi-omics study.
Zhang Z, Chen L, Shen H, Wang J, Yang J, Yang S, Zhang W, Jiang X, Wu X, Meng X, Zhao F, Gu W, Yin H, Wang L, Yu Y, Cheng L, Xu P, Fei D, Yu H, Shen X, Jin Y, Liu B, Sun J, Ni H, Atreya MR, Elbers PWG, Ho KM, Celi LA; Chinese Multi-omics Advances In Sepsis (CMAISE) Consortium. Zhang Z, et al. Among authors: jin y. Nat Commun. 2025 Nov 24;16(1):10328. doi: 10.1038/s41467-025-65271-4. Nat Commun. 2025. PMID: 41285725 Free PMC article.
Clinical consensus on vestibular infant screening.
Yang J, Shen J, Jin Y, Chen J, Zhang Q, Lu L, Chen X, Yu H, Xie W, Dai Q, Fang L, Huang Y, Tong B, Gao X, Qian X, Yu L, Zhang D, Fu Y, Zhang J, Li W, Marques P, Widdershoven J, van de Berg R, Young YH, Pyykkö I, Kaga K, Dasgupta S, Duan M. Yang J, et al. Among authors: jin y. Eur Arch Otorhinolaryngol. 2025 Nov 23. doi: 10.1007/s00405-025-09833-8. Online ahead of print. Eur Arch Otorhinolaryngol. 2025. PMID: 41276659 Review.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: jin y. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
24,486 results
You have reached the last available page of results. Please see the User Guide for more information.